Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777610 | 0.86 | PSIP1 (0.56) | HCRTR2GBA1ALDH1A1KAT6AKMT2A | |
| SCHEMBL3645517 | 0.81 | CA2 (0.47) | HCRTR2GBA1KAT6AKMT2AMEN1 | |
| SCHEMBL1272371 | 0.81 | GBA1 (0.40) | HCRTR2GBA1ALDH1A1KAT6AKMT2A | |
| SCHEMBL17942342 | 0.80 | MEN1 (0.46) | HCRTR2GBA1ALDH1A1KAT6AKMT2A | |
| SCHEMBL30833518 | 0.80 | MEN1 (0.46) | HCRTR2GBA1ALDH1A1KAT6AKMT2A | |
| SCHEMBL6098155 | 0.79 | KMT2A (0.58) | HCRTR2ALDH1A1KMT2AMEN1PSIP1 | |
| SCHEMBL1271749 | 0.79 | CA2 (0.50) | PTGDR2HCRTR2GBA1KAT6AKMT2A | |
| SCHEMBL5636466 | 0.79 | NFE2L2 (0.43) | HCRTR2GBA1KAT6AKMT2AMEN1 | |
| SCHEMBL1271000 | 0.78 | CA2 (0.54) | PTGDR2HCRTR2GBA1ALDH1A1KAT6A | |
| SCHEMBL3509889 | 0.78 | PNMT (0.46) | PTGDR2HCRTR2KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112135-A1 | Imidazo [1,2-A] Pyridine Compounds | WYETH LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| EP-2231617-A1 | BENZIMIDAZOLE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231660-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2217610-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112135-A1 | Imidazo [1,2-A] Pyridine Compounds | NR1H2, NR1H3, NR1H4 | PTGDR2 816/4885HCRTR2 501/4885GBA1 2039/4885 |
| US-20110034526-A1 | Benzimidazole Compounds | NR1H4, NR1H2, NR1H3 | PTGDR2 1570/4885HCRTR2 436/4885GBA1 1480/4885 |
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | PTGDR2 487/4885HCRTR2 219/4885GBA1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.